Change in quality of life, enjoyment, and satisfaction total score¹

For bipolar I and II depression in adults

Percentage change in quality of life at 6 weeks¹*

Change in Q-LES-Q-SF total score with CAPLYTA 42 mg or placebo as monotherapy¹

This graph depicts the change in quality of life as measured by Q-LES-Q-SF total score at 6 weeks for patients receiving CAPLYTA 42 mg or placebo as monotherapy.

Limitation: This secondary endpoint was not powered for statistical comparison and is descriptive only; results require cautious interpretation.

LSM=least squares mean; Q-LES-Q-SF=Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form.

*The Q-LES-Q-SF (Endicott et al, 1993) is a patient-reported, 14-item questionnaire that uses a 5-point rating scale from very poor to very good to assess patient satisfaction with a variety of items. Scores are summed to provide a raw total score ranging from 14 to 70; the total raw score is converted to a percent score.¹ Baseline scores were 37.03 for CAPLYTA and 38.61 for placebo.

Q-LES-Q-SF scale description

The Q-LES-Q-SF asks the patient how satisfied in the past week they are with their²:

Physical health
Mood
Work
Household activities
Social relationships
Family relationships
Leisure time activities
Ability to function in daily life

Sexual drive/interest/performance
Economic status
Living/housing situation
Ability to get around physically without feeling dizzy or unsteady or falling
Vision in terms of ability to do work or hobbies
Overall sense of well-being
Medication satisfaction
Overall life satisfaction

Study design

Monotherapy study: 6‑week study that randomized 381 patients to either CAPLYTA 42 mg or placebo. Patients were generally moderately to markedly ill. Median age was 45 years (range 18 to 72 years). 58% were female, 91% were Caucasian, and 8% were African American.³ The primary efficacy measure was the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.

Full chart description

This graph depicts the change in quality of life as measured by Q-LES-Q-SF total score at 6 weeks for patients receiving CAPLYTA 42 mg or placebo as monotherapy.

Patients on CAPLYTA showed an LSM change from baseline Q-LES-Q-SF score of 18.7 percentage points compared to 13.4 with placebo.

See the results of CAPLYTA in a post hoc analysis of
bipolar II depression pooled data

BP II Pooled Data

Change in quality of life, enjoyment, and satisfaction total score1

For bipolar I and II depression in adults

Percentage change in quality of life at 6 weeks1*

Change in Q-LES-Q-SF total score with CAPLYTA 42 mg or placebo as monotherapy1

View study design & full chart description

Change in quality of life, enjoyment, and satisfaction total score¹

Percentage change in quality of life at 6 weeks¹*

Change in Q-LES-Q-SF total score with CAPLYTA 42 mg or placebo as monotherapy¹